EIR Biopharma, a preclinical biotech developing in-licensed therapies for eye diseases, withdrew its plans for an initial public offering on Monday. It had filed in February 2026 to raise $17 million by offering 3.8 million shares at a price range of $4 to $5.
The San Francisco, CA-based company was founded in 2022. It had planned to list on the NYSE American but had not selected a symbol (RC ticker: EIRB.RC). Kingswood Capital Markets was set to be the sole bookrunner on the deal.


